GlaxoSmithKline to pay $41M over poor drugs

In a settlement, GlaxoSmithKline has agreed to pay almost $41 million over allegations the manufacturer sold faulty drugs made at a former factory in Puerto Rico. The sum will be shared by 37 states and the District of Columbia. This case follows another in which the company agreed to pay $750 million as part of a plea agreement with the U.S. Department of Justice last year. Government attorneys